This article was originally published in The Gray Sheet
Second $5 mil. installment of total $10 mil. Series A financing from Credit Suisse First Boston, Cyberfund and Hammer Capital is triggered by initial scale-up of the LifeShirt ambulatory monitoring system. The device, which continuously collects respiratory and heart rate data, blood-oxygen saturation levels, ECG waveform and systolic and diastolic heart function measures, will now be clinically evaluated in preparation for a 510(k) submission, Ventura, California-based VivoMetrics reports
You may also be interested in...
The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.
Medicinal products authorities will consider a medtech notified body opinion on the device element of a drug/device combination product. A new position paper explains how roles and responsibilities are shared between medtech and medicinal product experts.
A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.